

# ForPatients

by Roche

Malignant Melanoma

## A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

**Trial Status**  
Completed

**Trial Runs In**  
19 Countries

**Trial Identifier**  
NCT01689519 2012-003008-11  
GO28141

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma, as measured by progression-free survival (PFS), assessed by the study site investigator.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT01689519 2012-003008-11 GO28141**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---